Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
about
Rituximab for thyroid-associated ophthalmopathyRituximab for thyroid-associated ophthalmopathyObinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomasCritical appraisal of rituximab in the maintenance treatment of advanced follicular lymphomaAntiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsCD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytesSubcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeysTRAF3 deficiency promotes metabolic reprogramming in B cellsImmunogenicity and other problems associated with the use of biopharmaceuticals.A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesAn observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.Nanoscale ligand spacing influences receptor triggering in T cells and NK cellsRelapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemiaSymptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.Vaccines in the Treatment of Substance AbusePhase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphomaNK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infectionsA phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disordersPopulation pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Immunological risk factors for infection after immunosuppressive and biologic therapies.Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?Hepatitis C and non-Hodgkin lymphoma: the clinical perspective.Rituximab for chronic lymphocytic leukemia.Improved analytical methods for the detection and quantification of neutralizing antibodies to biopharmaceuticals.Cost-effectiveness of rituximab in follicular lymphoma.The role of autoantibodies in autoimmune hepatitis type 2.Multifocal motor neuropathy: current therapies and novel strategies.
P2860
Q24202845-72D6D512-25E8-4563-AE3C-1553563A623BQ24235160-BB3B9AFE-790D-4E03-9998-8C6C3191640AQ26751002-33598425-11FF-4438-84B0-5AAF16962FF4Q26775837-405A48FF-7B93-4F58-8F5E-C32D9D7C2CEDQ26801716-B5098320-C254-420E-9514-529FEACBE9BAQ26849243-57ED4560-5B7A-41AE-975D-1913BB1D4050Q27341786-D1331052-58C6-4564-93CD-11B787FF993FQ28535043-64AC6BDC-23BE-4E08-8C41-3A96286E2E65Q28820861-A70C18AE-353F-41F4-9BCA-0184F3C9BA40Q33416851-60BF84FF-D4D9-46A9-8AA2-99A5B8250991Q33431680-E1B01F45-A9D9-45BD-AB6E-E210BF0098F2Q33574197-2ED4A9E4-4E09-49A1-98C5-6647754D9857Q33665611-FBD83DB8-F0BA-464D-BB03-87571329253BQ34773987-2EC74F4D-E60F-46E9-B2EC-696257BB29C9Q34886056-EDC0CC9A-3E69-46C0-AAD0-E3627102EFA3Q35093521-6429716F-0CB2-4F10-9B2D-AA19CB7FA5A1Q35216949-49262FB1-4CA7-43FD-9E8E-F29A08109E0CQ35566828-276310B5-7983-45F6-BDDD-80C9D1527737Q35740894-BD1DCEE4-E0BA-4CEE-B215-201FF7DDD432Q35760142-310B2159-09B1-4ED5-8A2A-709434E10E1EQ35776992-2E4BBC04-7C99-4E43-9D65-AD5101ED273BQ36049914-9F7EF704-A9E2-40F2-979F-0432DB345BDCQ36612574-0A0877A4-3084-4DBC-9493-5B960DE6390DQ36655861-1975B78D-A10F-4164-B467-A5E0A2CE0F48Q36801911-2E2CDB90-2890-4293-ADE2-7250D7684BEFQ36814614-EA9CE8E4-B95A-46A6-9192-D50E03CD2491Q37205138-176E3B5D-5A8C-4E89-B6D3-6ADAA4E6926EQ37265471-A0B32C07-C3E6-4764-B32D-F059B4BF76F0Q37369319-60A9461C-C615-4DD4-8357-56907BC77950Q37863518-A9B1111F-3D10-40E8-9B60-BEF6CA1154C5Q37866341-92FBC8B4-59A8-43EB-88F4-713137D7E4FBQ37866813-2117439C-A198-478D-994F-D33CF0127DA1Q37875060-003CD3AB-E12D-4ED3-8334-BB29CDDA9854Q37912214-9BAAE512-1D6D-47DF-9E7C-1195D8993F87Q37961614-D1C2756E-8234-4B68-9234-7A038E46005FQ37988562-77B35688-56DA-4856-B151-67E37450D53BQ38046653-D4C4E3D1-AA4A-4FCE-8F67-C95A9162AD92Q38058840-E116BF6D-B5D1-4457-AE81-EE64AD0C6B49Q38085031-4F696B5E-4F83-4D92-8A55-6AEEA2C38A9EQ38091664-3419B6D4-F022-4902-9F21-6CF51D04C1C5
P2860
Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@ast
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@en
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@nl
type
label
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@ast
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@en
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@nl
prefLabel
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@ast
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@en
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@nl
P1433
P1476
Rituximab: a review of its use ...... diffuse large B-cell lymphoma.
@en
P304
P356
10.2165/11201110-000000000-00000
P577
2010-07-01T00:00:00Z
P6179
1030496969